CD22 and cancer: GSEA confirmed that ARIH2 is significantly associated with pathways such as CD22-mediated BCR regulation, FcγR activation, FcγRI-mediated MAPK activation, FcγRIIIA-mediated IL-10 synthesis, initial triggering of complement, DNA damage and cellular response via ATR, cell cycle regulation, ECM regulation, pathways in cancer, and regulation of TP53 activity and other relevant pathways, suggesting that ARIH2 may play a significant role in immune and tumor progression pathways.